Post
Health Canada approves third stage of ProJenX’s ALS trial
US-based clinical-stage biotech ProJenX has been given authorisation by Health Canada to launch the final part of its Phase I …
New study challenges current age-based colorectal cancer screening guidelines
Colorectal cancer (CRC) is responsible for more than 50,000 deaths per year and is the third most fatal type of …
Candel downsizes to focus on oncolytic virus-based cancer therapies
Candel Therapeutics has fired approximately 50% of its workforce in an effort to extend its cash runway into Q4 FY …
CTO Europe 2023: Reflections on drug development through the phases
Precision medicine oncology trial designs improve the likelihood of a drug’s approval by 38%, based on a presentation held by …
How to manage temperature-controlled shipments in unpredictable climate zones
Drugs have very specific temperature and storage requirements that must be considered at every point in the supply chain. Temperatures …
Arrowhead seeks regulatory clearance for Type 1 myotonic dystrophy trial
Arrowhead Pharmaceuticals has submitted an application seeking regulatory clearance to commence a Phase I/IIa clinical trial of its investigational RNA interference (RNAi) …
Merck reports data from Phase III pneumococcal vaccine trial
Merck (MSD) has reported data from the Phase III STRIDE-3 clinical trial of its investigational 21-valent pneumococcal conjugate vaccine, V116, for usage …
FDA grants IND clearance for Carisma’s solid tumour cell therapy trial
The US Food and Drug Administration (FDA) has granted clearance for Carisma Therapeutics’ investigational new drug application (IND) to commence a Phase …
TOLREMO doses first subject in Phase I trial of TT125-802
TOLREMO therapeutics has dosed the first subject in a Phase I clinical trial of its lead candidate, TT125-802, in individuals …
Pharma’s path to Net Zero: Targeting Scope 3 emissions
Net zero emission targets have never been more relevant to society. This year alone, there have been 24 extreme weather …
ADVANZ leverages Veeva software to develop HCP platform
“We underwent such digital transformation in the last few years, that we engage better with our physicians and patients than …
Bayer’s stock drops to new 18-year low after asundexian trial termination
Bayer’s stock price has plummeted to its lowest since 2005 after a clinical trial investigating the anti-coagulant drug asundexian was …
CTO Europe 2023: Cancer clinical trials shift as sector goes digital
Building on the increased adoption of digital trial capabilities due to the Covid-19 pandemic, the future of clinical trials will …
MHRA approves Ethris’ Phase I trial for inhaled mRNA drug
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ethris’s Phase I trial to investigate its inhaled mRNA …
Rallybio outlines Phase II trial plans after positive Phase I data
Rallybio Corporation has outlined its Phase II trial plans after revealing positive preliminary data from a Phase I study investigating …